

Zeenaat Safdar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6694938/publications.pdf>

Version: 2024-02-01

31
papers

1,582
citations

567281
15
h-index

454955
30
g-index

31
all docs

31
docs citations

31
times ranked

2051
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	6.7	614
2	Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute. Pulmonary Circulation, 2015, 5, 435-465.	1.7	230
3	Management of Pulmonary Arterial Hypertension During Pregnancy. Chest, 2013, 143, 1330-1336.	0.8	143
4	Portopulmonary hypertension: An update. Liver Transplantation, 2012, 18, 881-891.	2.4	90
5	Critical Role for IL-18 in Spontaneous Lung Inflammation Caused by Autophagy Deficiency. Journal of Immunology, 2015, 194, 5407-5416.	0.8	67
6	Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2014, 2, 412-421.	4.1	58
7	Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs. Respiratory Medicine, 2011, 105, 818-827.	2.9	52
8	A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. Annals of the American Thoracic Society, 2020, 17, 1576-1582.	3.2	47
9	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulmonary Circulation, 2017, 7, 167-174.	1.7	29
10	Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. Journal of Heart and Lung Transplantation, 2020, 39, 464-472.	0.6	27
11	Pulmonary arterial hypertension in pregnant women. Therapeutic Advances in Respiratory Disease, 2013, 7, 51-63.	2.6	22
12	Spironolactone in pulmonary arterial hypertension: results of a crossover study. Pulmonary Circulation, 2020, 10, 1-8.	1.7	22
13	Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension. Southern Medical Journal, 2017, 110, 223-228.	0.7	19
14	Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension. Journal of Pulmonary & Respiratory Medicine, 2015, 05, .	0.1	18
15	Efficacy of 1, 5, and 20Âmg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. BMC Pulmonary Medicine, 2017, 17, 44.	2.0	17
16	Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oralÂbosentan. Respiratory Medicine, 2009, 103, 1688-1692.	2.9	15
17	Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2014, 175, 268-273.	1.7	15
18	Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Vascular Health and Risk Management, 2011, 7, 119.	2.3	14

#	ARTICLE	IF	CITATIONS
19	Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 399-408.	1.7	12
20	Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension. <i>Clinical Drug Investigation</i> , 2010, 30, 811-826.	2.2	11
21	Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension. <i>International Journal of Cardiovascular Research</i> , 2015, 04, .	0.1	11
22	Pulmonary artery diastolic pressure gradient as an indicator of severity of illness in patients with pulmonary hypertension related to left-sided heart disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 35-41.	2.6	10
23	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1601-1609.	3.2	8
24	Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 12, 195.	1.0	7
25	Use of Extracorporeal Membrane Oxygenation in Postpartum Management of a Patient with Pulmonary Arterial Hypertension. <i>Case Reports in Pulmonology</i> , 2018, 2018, 1-4.	0.3	6
26	Chronic Thromboembolic Pulmonary Hypertension Medical Management. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 29.	1.0	5
27	Effect of spironolactone use in pulmonary arterial hypertension “analysis from pivotal trial databases. <i>Pulmonary Circulation</i> , 2021, 11, 1-11.	1.7	5
28	Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-3.	1.7	4
29	Circulating Biomarkers in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 21-27.	0.1	2
30	Pulmonary hypertension: a woman's disease. <i>Texas Heart Institute Journal</i> , 2013, 40, 302-3.	0.3	2
31	Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol. <i>Case Reports in Pulmonology</i> , 2020, 2020, 1-4.	0.3	0